Dutch research published in 2012 into the prophylaxis of recurrent urinary tract infections in (post) menopausal women has resulted in significant changes in treatment.
Both the regular media and the medical press, including NTVG, Doctors Net, have given much attention to this publication.
The outcome, an alarming degree of resistance development by antibiotic prophylaxis, has contributed to the fact that non-antibiotic treatment with Lactobacillus Rhamnosus GR-1® plus Lactobacillus Reuteri RC-14® for recurrent urinary tract infections in (post) menopausal women counts as an alternative that is almost as effective.
For the Working Group on Antibiotic Policy Foundation (SWAB), the research was reason to adjust its guidelines for the treatment of recurrent urinary tract infections and to include treatment with Lactobacillus Rhamnosus GR-1® plus Lactobacillus Reuteri RC-14®.
Memidis Pharma markets Lactobacillus Rhamnosus GR-1® plus Lactobacillus Reuteri RC-14® in capsules of 5.4 billion units in the Netherlands under the name Bacilac Femina®.
Pack contains 30 capsules
Pharmacist purchase price ex. VAT: € 17,05
Consumer price incl. VAT: € 24,16